| __timestamp | Dynavax Technologies Corporation | Xencor, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 7461000 |
| Thursday, January 1, 2015 | 22180000 | 11960000 |
| Friday, January 1, 2016 | 37257000 | 13108000 |
| Sunday, January 1, 2017 | 27367000 | 17501000 |
| Monday, January 1, 2018 | 64770000 | 22472000 |
| Tuesday, January 1, 2019 | 74986000 | 24286000 |
| Wednesday, January 1, 2020 | 79256000 | 29689000 |
| Friday, January 1, 2021 | 100156000 | 38837000 |
| Saturday, January 1, 2022 | 131408000 | 47489000 |
| Sunday, January 1, 2023 | 152946000 | 53379000 |
Cracking the code
In the competitive landscape of biotechnology, understanding the financial strategies of key players is crucial. Over the past decade, Dynavax Technologies Corporation and Xencor, Inc. have demonstrated distinct approaches to managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Dynavax's SG&A expenses surged by approximately 760%, peaking in 2023. This reflects a strategic investment in scaling operations and expanding market reach. In contrast, Xencor's expenses grew by about 615% over the same period, indicating a more conservative growth strategy.
The year 2023 marked a significant divergence, with Dynavax's expenses nearly three times higher than Xencor's. This disparity highlights differing priorities and operational strategies. As the biotech industry continues to evolve, these financial insights provide a window into the strategic decisions shaping the future of these companies.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation
Operational Costs Compared: SG&A Analysis of BeiGene, Ltd. and Xencor, Inc.
United Therapeutics Corporation vs Xencor, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Neurocrine Biosciences, Inc. and Dynavax Technologies Corporation
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Dynavax Technologies Corporation
Dr. Reddy's Laboratories Limited or Xencor, Inc.: Who Manages SG&A Costs Better?
Jazz Pharmaceuticals plc vs Xencor, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Madrigal Pharmaceuticals, Inc. and Xencor, Inc.
Operational Costs Compared: SG&A Analysis of Bausch Health Companies Inc. and Xencor, Inc.
Ligand Pharmaceuticals Incorporated vs Dynavax Technologies Corporation: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.